睿知中国医院研究地图
候选清单

长沙中南大学湘雅

湖南省肿瘤医院

Hunan Cancer Hospital

在本站收录的 53 种疾病中,这家医院列在其中 10 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

湖南省肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma53 篇牵头论文牵头 2 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma7 篇牵头论文牵头 1 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma16 篇牵头论文牵头 1 项开放试验
  4. 胃癌Stomach cancer25 篇牵头论文牵头 2 项开放试验
  5. 脊索瘤Chordoma1 篇牵头论文
  6. 骨肉瘤Osteosarcoma8 篇牵头论文
  7. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  8. 多发性骨髓瘤Multiple myeloma0 篇牵头论文
  9. 特发性肺纤维化Idiopathic pulmonary fibrosis0 篇牵头论文
  10. IgA 肾病IgA nephropathy1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、胃肠道间质瘤、神经母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 53 篇,占 2.2%。

牵头论文
53
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
10
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 111120222023: 101020232024: 131320242025: 12122025

长沙有 5 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 12

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
    分期
    II期
    开始
    2025-01
    登记号
    NCT06788002

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:湖南省肿瘤医院;另有 2 家列出的医院为研究中心长沙

  2. 正在招募
    Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
    分期
    未注明
    开始
    2024-01
    登记号
    NCT06321939

    年龄 18 岁 至 未注明(登记的条件)

    牵头:湖南省肿瘤医院长沙

  3. 正在招募
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
    分期
    III期
    开始
    2026-04
    登记号
    NCT07235319

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 4 家列出的医院为研究中心南宁、广州、杭州、福州、长沙

  4. 正在招募
    Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2026-07
    登记号
    NCT07661771

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 6 家列出的医院为研究中心东莞、中山、佛山、广州、深圳、长沙

  5. 正在招募
    Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2026-09
    登记号
    NCT07796789

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 2 家列出的医院为研究中心广州、福州、长沙

  6. 正在招募
    QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    分期
    III期
    开始
    2025-05
    登记号
    NCT06749899

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 17 家列出的医院为研究中心上海、东莞、中山、佛山、南京、南宁、厦门、天津、广州、成都、武汉、福州、贵阳、长沙

  7. 正在招募
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    分期
    I/II期
    开始
    2025-11
    登记号
    NCT07258979

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、东莞、南宁、南昌、厦门、广州、成都、昆明、杭州、桂林、江门、海口、福州、重庆、长沙、韶关

  8. 正在招募
    喉咽清口服液防治鼻咽癌放射性口腔黏膜炎Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    分期
    III期
    开始
    2025-12
    登记号
    NCT07311772

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、南宁、常州、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

  9. 正在招募
    Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
    分期
    III期
    开始
    2025-11
    登记号
    NCT07328841

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心中山、南宁、广州、梧州、武汉、汕头、珠海、长沙

  10. 正在招募
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2025-11
    登记号
    NCT07328854

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心中山、南宁、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

  11. 正在招募
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    分期
    III期
    开始
    2024-03
    登记号
    NCT06239727

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙

  12. 正在招募
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
    分期
    I期
    开始
    2021-11
    登记号
    NCT05194982

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心广州、武汉、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题复发与转移放疗技术影像与人工智能
论文中的科室放疗科影像/核医学科病理/检验科耳鼻喉/头颈外科

这些论文过半是实验室或动物研究。

牵头的论文53
  1. CircCDYL promotes glycolysis to drive the progression of nasopharyngeal carcinoma.2026Journal of advanced research免费全文
  2. circSETD3 confers radiotherapy resistance in nasopharyngeal carcinoma by attenuating ER stress-induced autophagy and apoptosis via PDIA6 upregulation.2026Oncogene
  3. Reirradiation based on diffusion-weighted magnetic resonance imaging-guided dose- painting for locally advanced recurrent nasopharyngeal carcinoma: a phase 2 randomized controlled trial.2025BMC cancerRCT免费全文
  4. Early prediction of progression-free survival of patients with locally advanced nasopharyngeal carcinoma using multi-parametric MRI radiomics.2025BMC cancer免费全文
  5. Diagnostic value of BNLF2b antibody, dual-antibody testing and Epstein-Barr virus DNA in nasopharyngeal carcinoma: a prospective cohort study in Hunan Province, China.2025BMJ open免费全文
  6. Combining decitabine with radiotherapy to enhance nasopharyngeal carcinoma radiosensitivity via the TFAP2C-OTUD1-SLC25A11 axis.2025Cell death & disease免费全文
  7. circADARB1 enhances ZEB1 expression in an m6A-dependent manner to promote the invasion and migration of nasopharyngeal carcinoma.2025International journal of biological macromolecules
  8. CD38 inhibits ferroptosis to promote radiotherapy resistance in nasopharyngeal carcinoma by competitively binding to TRIM21 to stabilize SLC7A11 protein.2025International journal of biological macromolecules
  9. Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation.2025Molecular cancer免费全文
  10. CircCCNB1 inhibits vasculogenic mimicry by sequestering NF90 to promote miR-15b-5p and miR-7-1-3p processing in nasopharyngeal carcinoma.2025Molecular oncology免费全文
  11. O-GlcNAc-modified HOXA9 suppresses ferroptosis via promoting UBR5-mediated SIRT6 degradation in nasopharyngeal carcinoma.2025Neoplasia (New York, N.Y.)免费全文
  12. m6A modification-dependent upregulation of WNT2 facilitates M2-like macrophage polarization and perpetuates malignant progression of nasopharyngeal carcinoma.2025Oncogene
  13. Deep learning Radiopathomics based on pretreatment MRI and whole slide images for predicting overall survival in locally advanced nasopharyngeal carcinoma.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  14. circTP63-N suppresses the proliferation and metastasis of nasopharyngeal carcinoma via engaging with HSP90AB1 to modulate the YAP1/Hippo signaling pathway.2025Science China. Life sciences
  15. Nanocarriers Targeting Circular RNA ADARB1 Boost Radiosensitivity of Nasopharyngeal Carcinoma through Synergically Promoting Ferroptosis.2024ACS nano
  16. Distribution of regional lymph nodes metastasis in 870 cases of nasopharyngeal carcinoma and the suggestions for individualized elective prophylactic neck irradiation with intensity-modulated radiotherapy.2024Cancer medicine免费全文
  17. CircBRD7 attenuates tumor growth and metastasis in nasopharyngeal carcinoma via epigenetic activation of its host gene.2024Cancer science免费全文
  18. Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2.2024Cell death & disease免费全文
  19. A specific super-enhancer actuated by berberine regulates EGFR-mediated RAS-RAF1-MEK1/2-ERK1/2 pathway to induce nasopharyngeal carcinoma autophagy.2024Cellular & molecular biology letters免费全文
  20. Silencing AHNAK promotes nasopharyngeal carcinoma progression by upregulating the ANXA2 protein.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  21. METTL14 promotes lipid metabolism reprogramming and sustains nasopharyngeal carcinoma progression via enhancing m6A modification of ANKRD22 mRNA.2024Clinical and translational medicine免费全文
  22. BRD7 enhances the radiosensitivity of nasopharyngeal carcinoma cells by negatively regulating USP5/METTL3 axis-mediated homologous recombination repair.2024International journal of biological sciences免费全文
  23. FOXA1 enhances antitumor immunity via repressing interferon-induced PD-L1 expression in nasopharyngeal carcinoma.2024Journal for immunotherapy of cancer免费全文
  24. Integrative radiopathomics model for predicting progression-free survival in patients with nonmetastatic nasopharyngeal carcinoma.2024Journal of cancer research and clinical oncology免费全文
  25. CircCDYL2 bolsters radiotherapy resistance in nasopharyngeal carcinoma by promoting RAD51 translation initiation for enhanced homologous recombination repair.2024Journal of experimental & clinical cancer research : CR免费全文
  26. Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.2024Molecular cancer免费全文
  27. Evolution of radiation-induced temporal lobe injury after intensity-modulated radiation therapy in nasopharyngeal carcinoma: a large cohort retrospective study.2024Radiation oncology (London, England)免费全文
  28. Metabolic reprogramming in nasopharyngeal carcinoma: Mechanisms and therapeutic opportunities.2023Biochimica et biophysica acta. Reviews on cancer
  29. LPLUNC1 reduces glycolysis in nasopharyngeal carcinoma cells through the PHB1-p53/c-Myc axis.2023Cancer science免费全文
  30. USP7 inhibits the progression of nasopharyngeal carcinoma via promoting SPLUNC1-mediated M1 macrophage polarization through TRIM24.2023Cell death & disease免费全文
  31. JUN-induced super-enhancer RNA forms R-loop to promote nasopharyngeal carcinoma metastasis.2023Cell death & disease免费全文
  32. BRD7 inhibits enhancer activity and expression of BIRC2 to suppress tumor growth and metastasis in nasopharyngeal carcinoma.2023Cell death & disease免费全文
  33. Circular RNA circRILPL1 promotes nasopharyngeal carcinoma malignant progression by activating the Hippo-YAP signaling pathway.2023Cell death and differentiation
  34. ACSL4 promotes ferroptosis and M1 macrophage polarization to regulate the tumorigenesis of nasopharyngeal carcinoma.2023International immunopharmacology
  35. Anoikis resistance and immune escape mediated by Epstein-Barr virus-encoded latent membrane protein 1-induced stabilization of PGC-1α promotes invasion and metastasis of nasopharyngeal carcinoma.2023Journal of experimental & clinical cancer research : CR免费全文
  36. Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  37. Epstein-Barr virus microRNA miR-BART2-5p accelerates nasopharyngeal carcinoma metastasis by suppressing RNase Ⅲ endonuclease DICER1.2023The Journal of biological chemistry免费全文
  38. A novel oncogenic seRNA promotes nasopharyngeal carcinoma metastasis.2022Cell death & disease免费全文
  39. MRI-based radiomics nomogram for predicting temporal lobe injury after radiotherapy in nasopharyngeal carcinoma.2022European radiology
  40. Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Tr2022International journal of radiation oncology, biology, physicsRCT
  41. SPLUNC1 regulates LPS-induced progression of nasopharyngeal carcinoma and proliferation of myeloid-derived suppressor cells.2022Medical oncology (Northwood, London, England)
  42. Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop.2022Molecular cancer免费全文
  43. Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop.2022Molecular cancer免费全文
  44. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.2022Nature communications免费全文
  45. Characteristics of locoregional extension of unilateral nasopharyngeal carcinoma and suggestions for clinical target volume delineation.2022Radiation oncology (London, England)免费全文
  46. Circular RNA circCCNB1 inhibits the migration and invasion of nasopharyngeal carcinoma through binding and stabilizing TJP1 mRNA.2022Science China. Life sciences
  47. Butein promotes ubiquitination-mediated survivin degradation inhibits tumor growth and overcomes chemoresistance.2022Scientific reports免费全文
  48. Cyclophilin A binds to AKT1 and facilitates the tumorigenicity of Epstein-Barr virus by mediating the activation of AKT/mTOR/NF-κB positive feedback loop.2022Virologica Sinica免费全文
  49. Failure patterns and prognostic factors for cervical node-negative nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.2021Asia-Pacific journal of clinical oncology
  50. Epstein-Barr Virus-Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1.2021Cancer research免费全文
  51. Bioinformatics Analysis of the Signaling Pathways and Genes of Gossypol Induce Death of Nasopharyngeal Carcinoma Cells.2021DNA and cell biology
  52. Effects of Cognitive Behavioral Therapy for Depression and Anxiety, Response Rates and Adverse Events in Patients with Locoregional Advanced Nasopharyngeal Carcinoma.2021Integrative cancer therapies免费全文
  53. Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2.2021Molecular cancer免费全文
中文论文(未计入)1
  1. Relationship of PI3K-Akt/mTOR/AMPK signaling pathway genetic mutation with efficacy and prognosis in nasopharyngeal carcinoma.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)26
  1. LDRT and Chemoimmunotherapy in NPC With Liver Metastasis正在招募NCT06788002牵头方II期2025-01 启动
  2. Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma正在招募NCT06321939牵头方2024-01 启动
  3. Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma状态不明NCT02481089牵头方2015-06 启动
  4. Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma正在招募NCT07796789研究中心III期2026-09 启动
  5. PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC正在招募NCT07235319研究中心III期2026-04 启动
  6. Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma正在招募NCT07661771研究中心III期2026-07 启动
  7. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid正在招募NCT07311772研究中心III期2025-12 启动
  8. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy正在招募NCT07328841研究中心III期2025-11 启动
  9. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.正在招募NCT06749899研究中心III期2025-05 启动
  10. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.正在招募NCT07258979研究中心I/II期2025-11 启动
  11. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma正在招募NCT07328854研究中心III期2025-11 启动
  12. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response正在招募NCT06239727研究中心III期2024-03 启动
  13. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor正在招募NCT05194982研究中心I期2021-11 启动
  14. Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma进行中,不再招募NCT06712888研究中心III期2025-02 启动
  15. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT05126719研究中心II期2023-04 启动
  16. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)进行中,不再招募NCT05587374研究中心III期2023-08 启动
  17. Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma进行中,不再招募NCT05979961研究中心III期2023-09 启动
  18. A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer状态不明NCT06232863研究中心I期2023-01 启动
  19. To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer状态不明NCT05198531研究中心I/II期2022-01 启动
  20. Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma进行中,不再招募NCT05211232研究中心III期2022-06 启动
  21. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  22. Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma已完成NCT04823468研究中心不分期2021-07 启动
  23. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)已完成NCT03924986研究中心III期2019-03 启动
  24. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer已完成NCT03581786研究中心III期2018-10 启动
  25. Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma状态不明NCT03321539研究中心III期2017-10 启动
  26. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
PubMed 以外找到的论文(未计入)54
  1. 1390P Updated long term efficacy results of phase II study for becotatug vedotin combined with pucotenlimab in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)2025Annals of Oncology论文
  2. 1423P Real-world evidence of neoadjuvant immunotherapy in high-risk locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis2025Annals of Oncology论文
  3. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncology论文
  4. A Transcriptome Sequencing Analysis on Berberine-mediated Gene Expression in Nasopharyngeal Carcinoma cells2025Clinical Medicine and Pharmacology论文
  5. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  6. Aptamers Associated with Nasopharyngeal Carcinoma Metastasis2025Clinical Medicine and Pharmacology论文
  7. Association between high HBV-DNA viral load and liver metastasis risk in patients with nasopharyngeal carcinoma2025Virus Research论文
  8. Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.2025Journal of Clinical Oncology论文
  9. LBA35 Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, piv2025Annals of Oncology会议摘要
  10. Potential Collaborative Markers for Nasopharyngeal Carcinoma Diagnosis and Therapy: AGR2 and AKR1B102025Clinical Medicine and Pharmacology论文
  11. Serum tsRNA profile of Nasopharyngeal Carcinoma Patients with Various Chinese Medicine Syndrome2025Clinical Medicine and Pharmacology论文
  12. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncology会议摘要
  13. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncology会议摘要
  14. WITHDRAWN: 1383P Preliminary efficacy analysis of cetuximab-enhanced induction chemotherapy for locally advanced refractory nasopharyngeal carcinoma2025Annals of Oncology撤稿
  15. 402O Preliminary results of phase II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)2024Annals of Oncology论文
  16. Abstract CT113: A dose-exploring, randomized, open-label, Phase I study for toripalimab subcutaneous injection in patients with advanced nasopharyngeal carcinoma2024Cancer Research会议摘要
  17. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Research会议摘要
  18. Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study.2024Journal of Clinical Oncology会议摘要
  19. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncology会议摘要
  20. Long Term Effects of Cognitive Behavioral Therapy on Late Toxicities, Depressive and Anxiety Symptoms in Patients with Locoregional Advanced Nasopharyngeal Carcinoma Undergoing Chemoradiotherapy: A Randomized, Controlled Clinical Trial2024International Journal of Radiation Oncology*Biology*Physics论文
  21. Long Term Outcomes and Late Toxicity of Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting Radiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized, Controlled Clinical Trial2024International Journal of Radiation Oncology*Biology*Physics论文
  22. Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.2024Journal of Clinical Oncology会议摘要
  23. Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.2024Journal of Clinical Oncology会议摘要
  24. RETRACTED: METTL14 Promotes Lipid Metabolism Reprogramming and Sustains Nasopharyngeal Carcinoma Progression via Enhancing m6A Modification of ANKRD22 mRNA2024Research Square预印本
  25. Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomiz2024Journal of Clinical Oncology会议摘要
  26. 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma2023Annals of Oncology论文
  27. Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation.2023Journal of Clinical Oncology会议摘要
  28. Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.2023Journal of Clinical Oncology会议摘要
  29. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.2023Journal of Clinical Oncology会议摘要
  30. Data from Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L12023未列出期刊其他
  31. Distribution Pattern of Metastatic Lymph Nodes in 870 Cases of Nasopharyngeal Carcinoma: A Clue for Individualized Elective Prophylactic Neck Irradiation2023International Journal of Radiation Oncology*Biology*Physics论文
  32. Distribution pattern of metastatic lymph nodes in 870 cases of nasopharyngeal carcinoma: A clue for individualized elective prophylactic neck irradiation.2023Journal of Clinical Oncology会议摘要
  33. Dose Painting Radiotherapy Guided by Diffusion-Weighted Magnetic Resonance vs. 18F-FDG-PET/CT in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized, Controlled Clinical Trial2023International Journal of Radiation Oncology*Biology*Physics论文
  34. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncology会议摘要
  35. WITHDRAWN: Targeting the PLUNC-NLRP3 inflammasome axis could inhibit nasopharyngeal carcinoma lung metastasis2023Research Square预印本
  36. A Randomized Controlled Trial of Cognitive Behavior Therapy to Reduce Oral Mucositis in Patients with Locoregional Advanced Nasopharyngeal Carcinoma Undergoing Chemoradiotherapy2022International Journal of Radiation Oncology*Biology*Physics论文
  37. A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).2022Journal of Clinical Oncology会议摘要
  38. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Research会议摘要
  39. Four-year result of diffusion-weighted, MRI-guided, dose-painting radiotherapy following induction chemotherapy in patients with locally advanced recurrent nasopharyngeal carcinoma: A randomized controlled trial.2022Journal of Clinical Oncology会议摘要
  40. Mitoxantrone hydrochloride liposome injection in the treatment of recurrent/metastatic head and neck cancers: A multicenter, open-label, single-arm, phase Ⅰb study.2022Journal of Clinical Oncology会议摘要
  41. PRMT5 regulates the NAD-SIRT1-p53 signal axis by affecting the methylation of CD38 at R58 to promote malignant tumor cell proliferation2022Research Square预印本
  42. Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study.2022Journal of Clinical Oncology会议摘要
  43. Serum Level of Tumor-Specific Growth Factor in Patients with Cervical Cancer and Its Potential Prognostic Role2022ONCOLOGIE论文
  44. 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy2021Journal for ImmunoTherapy of Cancer会议摘要
  45. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncology论文
  46. A Randomized Controlled Trial of Cognitive Behavior Therapy for Reducing Anxiety and Depressive Symptoms in Patients With Locally Recurrent Nasopharyngeal Carcinoma Receiving Reirradiation2021International Journal of Radiation Oncology*Biology*Physics论文
  47. A Randomized Controlled Trial of Reirradiation Using Diffusion-Weighted MRI Guided Dose-Painting vs. CT-Based Radiotherapy for Locally Recurrent T3 to T4 Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physics论文
  48. A randomized controlled trial of cognitive behavior therapy for reducing anxiety and depressive symptoms in patients with locoregional advanced nasopharyngeal carcinoma.2021Journal of Clinical Oncology会议摘要
  49. A randomized phase II trial of diffusion-weighted MR imaging-guided radiotherapy plus chemotherapy versus standard chemoradiotherapy in locoregional advanced nasopharyngeal carcinoma.2021Journal of Clinical Oncology会议摘要
  50. Efficacy of Concurrent Chemoradiotherapy In Subgroups of Stage III Nasopharyngeal Carcinoma: An Analysis Based On 10-Year Follow-Up2021Research Square预印本
  51. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncology会议摘要
  52. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要
  53. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncology会议摘要
  54. [Retracted] MicroRNA‑19a promotes nasopharyngeal carcinoma by targeting transforming growth factor β receptor 22021Experimental and Therapeutic Medicine论文

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.2%。

牵头论文
7
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 4420222023: 2220232024: 0020242025: 112025

长沙有 3 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
    分期
    I期
    开始
    2025-08
    登记号
    NCT07090499

    年龄 18 岁 至 未注明(登记的条件)

    牵头:湖南省肿瘤医院长沙

  2. 正在招募
    Chemoradiotherapy in Unresectable Esophageal Cancer
    分期
    I/II期
    开始
    2019-10
    登记号
    NCT04278287

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国医学科学院肿瘤医院;另有 4 家列出的医院为研究中心北京、南京、安阳、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题分子标志物与基因手术新辅助与综合治疗
论文中的科室消化/肝病科放疗科肿瘤内科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文7
  1. MTHFD2 promotes esophageal squamous cell carcinoma progression via m6A modification‑mediated upregulation and modulation of the PEBP1‑RAF1 interaction.2025International journal of molecular medicine免费全文
  2. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.2023Frontiers in immunology免费全文
  3. High FN1 expression is associated with poor survival in esophageal squamous cell carcinoma.2023Medicine免费全文
  4. Histone Demethylase GASC1 Inhibitor Targeted GASC1 Gene to Inhibit the Malignant Transformation of Esophageal Cancer through the NOTCH-MAPK Signaling Pathway.2022Annals of clinical and laboratory science
  5. OPN Promotes Cell Proliferation and Invasion through NF-κB in Human Esophageal Squamous Cell Carcinoma.2022Genetics research免费全文
  6. Network analysis of genes associated with esophageal squamous cell carcinoma progression.2022Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  7. Comparison of tumor-associated and nontumor-associated esophageal mucosa microbiota in patients with esophageal squamous cell carcinoma.2022Medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)24
  1. A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)状态不明NCT04767295牵头方II期2021-03 启动
  2. Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer状态不明NCT02527057牵头方2014-10 启动
  3. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors正在招募NCT07090499牵头方(推断)I期2025-08 启动
  4. Chemoradiotherapy in Unresectable Esophageal Cancer正在招募NCT04278287研究中心I/II期2019-10 启动
  5. A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors进行中,不再招募NCT06238479研究中心I期2024-03 启动
  6. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  7. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  8. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  9. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  10. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors状态不明NCT05602792研究中心I/II期2020-04 启动
  11. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  12. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  13. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)已完成NCT04210115研究中心III期2020-02 启动
  14. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  15. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  16. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  17. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
  18. Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.已完成NCT06190652研究中心2018-10 启动
  19. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  20. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  21. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)已完成NCT02649361研究中心II期2016-01 启动
  22. Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma已完成NCT02395705研究中心III期2015-06 启动
  23. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02611700研究中心III期2015-11 启动
  24. Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial状态不明NCT02319187研究中心III期2014-12 启动
PubMed 以外找到的论文(未计入)14
  1. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physics论文
  2. PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study2025Journal of Thoracic Oncology论文
  3. The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncology会议摘要
  4. A phase I/II study of C019199 in combination with sintilimab in advanced malignancy.2024Journal of Clinical Oncology会议摘要
  5. AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): A single-arm, open-label, multicenter, phase Ib study.2024Journal of Clinical Oncology会议摘要
  6. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Research会议摘要
  7. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  8. Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical t2024Journal of Clinical Oncology会议摘要
  9. “Pacific” Modality in Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis of a Real-World Multicenter Study2024International Journal of Radiation Oncology*Biology*Physics论文
  10. A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.2023Journal of Clinical Oncology会议摘要
  11. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncology论文
  12. Comprehensive analysis based on methylation microarrays and single-cell transcriptomics in esophageal squamous cell carcinoma2022Research Square预印本
  13. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  14. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 16 篇,占 0.1%。

牵头论文
16
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
8
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 5520232024: 5520242025: 222025

长沙有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
    分期
    II期
    开始
    2024-05
    登记号
    NCT06406634

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:湖南省肿瘤医院长沙

  2. 正在招募
    A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
    分期
    II期
    开始
    2025-03
    登记号
    NCT06742892

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心长沙

  3. 正在招募
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-05
    登记号
    NCT06954467

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、合肥、哈尔滨、沈阳、郑州、长沙

  4. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  5. 正在招募
    Phase 2 Study of WGI-0301 for Advanced HCC
    分期
    II期
    开始
    2024-07
    登记号
    NCT06309485

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心南昌、哈尔滨、成都、杭州、武汉、长沙

  6. 正在招募
    A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
    分期
    III期
    开始
    2024-08
    登记号
    NCT06371157

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心南京、杭州、郑州、长沙

  7. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

  8. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  9. 正在招募
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
    分期
    I/II期
    开始
    2022-12
    登记号
    NCT05652920

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、成都、杭州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现免疫与靶向药物
论文中的科室放疗科病理/检验科消化/肝病科普外/肝胆胰外科

这些论文过半是实验室或动物研究。

牵头的论文16
  1. Prognostic model construction and immune microenvironment analysis of pyroptosis-related genes in hepatocellular carcinoma based on single-cell RNA sequencing.2025Frontiers in immunology免费全文
  2. Exploring the heterogeneity of cancer-related fatigue in advanced hepatocellular carcinoma patients via latent profiles and influencing factors.2025Scientific reports免费全文
  3. Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma.2024Aging免费全文
  4. Exosomal PDL1 Suppresses the Anticancer Activity of CD8+ T Cells in Hepatocellular Carcinoma.2024Analytical cellular pathology (Amsterdam)免费全文
  5. The survival prediction analysis and preliminary study of the biological function of YEATS2 in hepatocellular carcinoma.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  6. let-7g sensitized liver cancer cells to 5-fluorouracil by downregulating ABCC10 expression.2024Chemical biology & drug design
  7. A multi-omic analysis reveals that Gamabufotalin exerts anti-hepatocellular carcinoma effects by regulating amino acid metabolism through targeting STAMBPL1.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  8. E2F1-mediated KDM4A-AS1 up-regulation promotes EMT of hepatocellular carcinoma cells by recruiting ILF3 to stabilize AURKA mRNA.2023Cancer gene therapy免费全文
  9. SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  10. Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score.2023Journal of cancer research and clinical oncologyRCT免费全文
  11. Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma.2023Journal of gastroenterology
  12. Diagnostic accuracy of circulating exosomal circRNAs in malignances: A meta-analysis and systematic review.2023Medicine免费全文
  13. Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.2022Frontiers in immunology免费全文
  14. Identification of key snoRNAs serves as biomarkers for hepatocellular carcinoma by bioinformatics methods.2022Medicine免费全文
  15. Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features.2021Abdominal radiology (New York)免费全文
  16. Differential Analysis of IncRNAs and mRNAs Expression in HCC and the Predictive Value of lncRNAs.2021Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
它在 ClinicalTrials.gov 上的全部试验(任何状态)36
  1. Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma正在招募NCT06406634牵头方II期2024-05 启动
  2. A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).状态不明NCT04826406牵头方II期2021-02 启动
  3. Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT状态不明NCT05530785牵头方(推断)不分期2022-08 启动
  4. A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy正在招募NCT06742892研究中心II期2025-03 启动
  5. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma正在招募NCT06954467研究中心II期2025-05 启动
  6. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  7. Phase 2 Study of WGI-0301 for Advanced HCC正在招募NCT06309485研究中心II期2024-07 启动
  8. A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma正在招募NCT06371157研究中心III期2024-08 启动
  9. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  10. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  11. Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC正在招募NCT05652920研究中心I/II期2022-12 启动
  12. Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.已终止NCT06320080研究中心I期2024-05 启动
  13. A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).已终止NCT05975645研究中心I期2023-08 启动
  14. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  15. A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC进行中,不再招募NCT05319431研究中心II期2022-06 启动
  16. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  17. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  18. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab进行中,不再招募NCT04770896研究中心III期2021-04 启动
  19. Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma状态不明NCT04605185研究中心I期2021-01 启动
  20. Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)已完成NCT04740307研究中心II期2021-03 启动
  21. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  22. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  23. YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)已完成NCT04000737研究中心II期2020-01 启动
  24. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  25. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  26. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  27. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动
  28. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)已完成NCT03713593研究中心III期2018-12 启动
  29. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma已完成NCT03434379研究中心III期2018-03 启动
  30. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  31. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects已终止NCT03236649研究中心III期2017-09 启动
  32. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC已完成NCT03516071研究中心II期2017-05 启动
  33. Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients状态不明NCT02956772研究中心II期2016-11 启动
  34. A Study to Evaluate SHR-1210 in Subjects With Advanced HCC已完成NCT02989922研究中心II期2016-11 启动
  35. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma已完成NCT02508467研究中心I期2015-07 启动
  36. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)已完成NCT02112656研究中心III期2014-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 0.3%。

牵头论文
25
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 6620222023: 6620232024: 2220242025: 662025

长沙有 4 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
    分期
    不分期
    开始
    2025-05
    登记号
    NCT07098026

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:湖南省肿瘤医院长沙

  2. 正在招募
    Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
    分期
    未注明
    开始
    2024-01
    登记号
    NCT06543108

    年龄 18 岁 至 90 岁(登记的条件)

    牵头:湖南省肿瘤医院长沙

  3. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  4. 正在招募
    A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    分期
    II期
    开始
    2025-02
    登记号
    NCT06760819

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、杭州、长沙

  5. 正在招募
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    分期
    I期
    开始
    2025-07
    登记号
    NCT07066657

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、杭州、武汉、郑州、重庆、长沙

  6. 正在招募
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    分期
    II/III期
    开始
    2024-02
    登记号
    NCT06221748

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、厦门、哈尔滨、徐州、成都、昆明、武汉、济南、郑州、长沙、青岛

  7. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  8. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛

  9. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术化疗与综合治疗影像与人工智能
论文中的科室普外/肝胆胰外科肿瘤内科消化/肝病科影像/核医学科
牵头的论文25
  1. GLIS2 Promotes Epithelial-Mesenchymal Transition and Gastric Cancer Progression by Regulating BGN to Activate the Wnt/β-Catenin Pathway.2026The Kaohsiung journal of medical sciences免费全文
  2. Value of Post-NAC CT-based Node-RADS score for Predicting residual lymph node metastasis and survival outcome of locally advanced gastric cancer.2025Abdominal radiology (New York)
  3. Engineering a nano-drug delivery system to regulate m6A modification and enhance immunotherapy in gastric cancer.2025Acta biomaterialia
  4. Added value of pretreatment CT-based Node-RADS score for predicting survival outcome of locally advanced gastric cancer: compared with clinical N stage.2025BMC cancer免费全文
  5. Bone Metastasis Mediates Poor Prognosis in Early-Onset Gastric Cancer: Insights Into Immune Suppression, Coagulopathy, and Inflammation.2025Cancer medicine免费全文
  6. Evaluating the diagnostic performance of [18F]ALF-NOTA-FAPI-04 PET/CT in gastric cancer: a comparative study with [18F]FDG PET/CT.2025European radiology免费全文
  7. Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study.2025World journal of surgical oncology免费全文
  8. Nomogram to predict overall survival of patients receiving radical gastrectomy and incomplete peri-operative adjuvant chemotherapy for stage II/III gastric cancer: a retrospective bi-center cohort study.2024BMC cancer免费全文
  9. Prognostic factors and adjuvant chemotherapy efficacy in stage I gastric cancer patients: a retrospective analysis.2024BMC gastroenterology免费全文
  10. RNA helicase DDX5-induced circPHF14 promotes gastric cancer cell progression.2023Aging免费全文
  11. Effect of tumor exosome-derived Lnc RNA HOTAIR on the growth and metastasis of gastric cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  12. Classification of precancerous lesions based on fusion of multiple hierarchical features.2023Computer methods and programs in biomedicine
  13. Prognostic value of post-operative serum procalcitonin in gastric adenocarcinoma patients undergoing radical gastrectomy: propensity score matching analysis of extended cohort from a prospective bi-center study.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  14. Exosomal PD‑L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B‑cell lymphoma.2023Oncology reports免费全文
  15. YWHAH activates the HMGA1/PI3K/AKT/mTOR signaling pathway by positively regulating Fra-1 to affect the proliferation of gastric cancer cells.2023Oncology research免费全文
  16. Association among prognostic nutritional index, post-operative infection and prognosis of stage II/III gastric cancer patients following radical gastrectomy.2022European journal of clinical nutrition免费全文
  17. Inhibition MNK-eIF4E-β-catenin preferentially sensitizes gastric cancer to chemotherapy.2022Fundamental & clinical pharmacology
  18. Kinesin family member 2A links with advanced tumor stage, reduced chemosensitivity and worse prognosis in gastric cancer.2022Journal of clinical laboratory analysis免费全文
  19. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.2022Nature communications免费全文
  20. hsa_circ_0067514 suppresses gastric cancer progression and glycolysis via miR-654-3p/LATS2 axis.2022Neoplasma
  21. A novobiocin derivative, XN4, triggers ferroptosis in gastric cancer cells via the activation of NOX4.2022Pharmaceutical biology免费全文
  22. Association Among Blood Transfusion, Postoperative Infectious Complications, and Cancer-Specific Survival in Patients with Stage II/III Gastric Cancer After Radical Gastrectomy: Emphasizing Benefit from Adjuvant Chemotherapy.2021Annals of surgical oncology免费全文
  23. ASO Author Reflections: Association Between Perioperative Blood Transfusion, Infections, and Prognosis of Stage II/III Gastric Cancer Patients.2021Annals of surgical oncology
  24. The effects and mechanism of α-mangostin on chemosensitivity of gastric cancer cells.2021The Kaohsiung journal of medical sciences免费全文
  25. The effect of Helicobacter pylori eradication on prognosis of postoperative early gastric cancer: a multicenter study.2021World journal of surgical oncology免费全文
中文论文(未计入)2
  1. [Advances in the role and mechanism of tumor-associated neutrophils in gastric cancer].2025Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  2. Genetic variation of YWHAE gene-"Switch" of disease control.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)30
  1. Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer正在招募NCT07098026牵头方不分期2025-05 启动
  2. Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer正在招募NCT06543108牵头方2024-01 启动
  3. Procalcitonin to Predict Infection After Gastrectomy for Gastric Cancer已完成NCT03780439牵头方(推断)2018-06 启动
  4. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  5. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)正在招募NCT06760819研究中心II期2025-02 启动
  6. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors正在招募NCT07066657研究中心I期2025-07 启动
  7. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  8. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy正在招募NCT06221748研究中心II/III期2024-02 启动
  9. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  10. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  11. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  12. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors进行中,不再招募NCT06257264研究中心I期2024-03 启动
  13. EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer已撤回NCT05411679研究中心II期2023-04 启动
  14. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  15. To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors已完成NCT05253053研究中心I/II期2022-04 启动
  16. A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.状态不明NCT05141747研究中心II期2022-01 启动
  17. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  18. Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)进行中,不再招募NCT05382364研究中心I期2022-06 启动
  19. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)已终止NCT04933227研究中心II期2021-08 启动
  20. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  21. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  22. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  23. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  24. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  25. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  26. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动
  27. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer已完成NCT02898077研究中心III期2017-03 启动
  28. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  29. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  30. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

长沙有 6 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.4%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 1120222023: 1120232024: 1120242025: 112025

长沙有 14 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    分期
    II期
    开始
    2023-06
    登记号
    NCT05830123

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、广州、杭州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文8
  1. Identification of EMT-related subtype and a 9 genes signature predicts the prognosis in osteosarcoma.2026Connective tissue research
  2. COPS5 regulates osteosarcoma progression by upregulating KHSRP to promote Per2 mRNA decay.2025Experimental cell research
  3. Tenuigenin inhibits osteosarcoma growth via CIP2A/PP2A/NF-κB axis.2024Cancer chemotherapy and pharmacology
  4. The Eph/Ephrin system in primary bone tumor and bone cancer pain.2023Aging
  5. FDG PET/CT of Primary Ewing Sarcoma of the Peritoneum.2022Clinical nuclear medicine
  6. MIR205 host gene (MIR205HG) drives osteosarcoma metastasis via regulating the microRNA 2114-3p (miR-2114-3p)/twist family bHLH transcription factor 2 (TWIST2) axis.2021Bioengineered
  7. LncRNA HOTTIP facilitates cell proliferation, invasion, and migration in osteosarcoma by interaction with PTBP1 to promote KHSRP level.2021Cell cycle (Georgetown, Tex.)
  8. 3D printing guide plate for accurate hemicortical bone tumor resection in metaphysis of distal femoral: a technical note.2021Journal of orthopaedic surgery and research
早期论文(2016–2020 年)1
  1. Overexpression of miR-422a inhibits cell proliferation and invasion, and enhances chemosensitivity in osteosarcoma cells.2016Oncology reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas正在招募NCT05830123研究中心II期2023-06 启动
  2. TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors已终止NCT06438783研究中心I期2024-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

长沙有 3 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
    分期
    I期
    开始
    2025-05
    登记号
    NCT06926283

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、杭州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文1
  1. FDG PET/CT of Primary Ewing Sarcoma of the Peritoneum.2022Clinical nuclear medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors正在招募NCT06926283研究中心I期2025-05 启动
  2. A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma已完成NCT05046314研究中心II期2024-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年没有牵头多发性骨髓瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

长沙有 4 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    分期
    I/II期
    开始
    2021-09
    登记号
    NCT04973605

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年没有牵头特发性肺纤维化的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长沙有 7 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

长沙有 7 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

湖南省肿瘤医院

Hunan Cancer Hospital

长沙

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Hunan Provincial Tumor Hospital; Graduate Collaborative Training Base of Hunan Cancer Hospital; Hunan Provincial Cancer Hospital; Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya; and Hunan Cancer Hospital; Graduates Collaborative Training Base of Hunan Cancer Hospital; Hunan Cancer Hospital of Central South University; Hunan Cancer Hospital of Xiangya School

提出更正下载数据